Kura Oncology’s (KURA) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Kura Oncology (NASDAQ:KURA) in a research note issued to investors on Wednesday,Benzinga reports. HC Wainwright currently has a $32.00 price target on the stock.

Other research analysts have also recently issued research reports about the company. Lifesci Capital upgraded Kura Oncology to a “strong-buy” rating in a research note on Tuesday, October 22nd. StockNews.com upgraded Kura Oncology from a “sell” rating to a “hold” rating in a research note on Tuesday. Wedbush reiterated an “outperform” rating and set a $37.00 price objective on shares of Kura Oncology in a research note on Monday, November 4th. Cantor Fitzgerald reissued an “overweight” rating on shares of Kura Oncology in a report on Wednesday, November 6th. Finally, UBS Group began coverage on Kura Oncology in a report on Thursday, October 24th. They issued a “buy” rating and a $27.00 price objective for the company. Two analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $28.83.

Kura Oncology Stock Down 3.5 %

Shares of KURA traded down $0.57 on Wednesday, reaching $15.92. The stock had a trading volume of 979,575 shares, compared to its average volume of 895,395. The firm has a market capitalization of $1.24 billion, a price-to-earnings ratio of -6.75 and a beta of 0.86. The company has a debt-to-equity ratio of 0.02, a quick ratio of 11.47 and a current ratio of 11.47. The company has a 50-day simple moving average of $18.50 and a 200-day simple moving average of $19.92. Kura Oncology has a 12-month low of $8.80 and a 12-month high of $24.17.

Hedge Funds Weigh In On Kura Oncology

Several large investors have recently made changes to their positions in KURA. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Kura Oncology by 12.8% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 40,970 shares of the company’s stock valued at $874,000 after acquiring an additional 4,659 shares in the last quarter. SG Americas Securities LLC purchased a new stake in shares of Kura Oncology in the first quarter worth about $110,000. ProShare Advisors LLC lifted its position in shares of Kura Oncology by 9.7% in the first quarter. ProShare Advisors LLC now owns 18,014 shares of the company’s stock worth $384,000 after buying an additional 1,588 shares in the last quarter. Entropy Technologies LP purchased a new stake in shares of Kura Oncology in the first quarter worth about $218,000. Finally, Vanguard Group Inc. lifted its position in shares of Kura Oncology by 0.7% in the first quarter. Vanguard Group Inc. now owns 4,065,903 shares of the company’s stock worth $86,726,000 after buying an additional 28,212 shares in the last quarter.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.